PHARMARON BEIJING H YC1 Unternehmensprofil
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the Peoples Republic of China.
Vorstand
Dr. Boliang Lou Ph.D.
Vorsitzender & GESCHÄFTSFÜHRER
Herr Xiaoqiang Lou EMBA
Mitbegründer, Präsident, COO & Geschäftsführender Direktor
Herr Shing Chung Li C.F.A., CPA
CFO, Sekretär des Verwaltungsrats & Vertreter der Arbeitnehmer Direktor
Dr. Hua Yang Ph.D.
Wissenschaftlicher Leiter & Stellvertretender Leiter
Frau Bei Zheng M.A., M.A.
Executive VP & Exekutivdirektor
Dr. Connie Sun Ph.D.
Senior VP & Globaler Leiter der Geschäftsentwicklung für kleine Moleküle
Frau Celina Zhong M.B.A.
Senior-Vizepräsidentin für Personalwesen
Frau Katherine Lee M.B.A.
Geschäftsführender Direktor
Herr Stephen Lewinton
Senior Vice President für das Vereinigte Königreich
Dr. Jingqi Huang
Stellvertretender Leiter der Abteilung In-vivo-Pharmakologie
Aktionärsstruktur
81,711%
Freefloat
60,678%
Individuelle Aktionäre
21,033%
Institutionelle Aktionäre
Termine
| 25.04.2026 | Quartalsmitteilung |
| 30.03.2026 | Quartalsmitteilung |
Stammdaten
| Nennwert/Aktie | - |
| Land | Deutschland |
| Währung | EUR |
| Branche | |
| Aktientyp | - |
| Sektor | |
| Gattung | - |
Quelle: Leeway